2C-E: Difference between revisions
No edit summary |
m (Reverted edits by Dumbdumb123 (talk) to last revision by Dread) |
||
| (9 intermediate revisions by 8 users not shown) | |||
| Line 1: | Line 1: | ||
[[File:2ce.jpg|thumb| | [[File:2ce.jpg|thumb|150px|Vial of 2C-E with powder]] | ||
2C-E is a chemical of the [[2C-X]] series which is characterised by its particularly intense visuals and higher potency when compared with other members of the family. | '''2C-E''' is a chemical of the [[2C-X]] series which is characterised by its particularly intense visuals and higher potency when compared with other members of the family. | ||
= History = | == History == | ||
2C-E, like many of its close analogues, was first synthesized by Alexander Shulgin and published in PiHKAL. He was quite fond of it, granting it a place in his "Magical Half Dozen" alongside of [[DOM]], [[2C-B]], [[2C-T-2]] & 7 and [[mescaline]]. | 2C-E, like many of its close analogues, was first synthesized by Alexander Shulgin and published in PiHKAL. He was quite fond of it, granting it a place in his "Magical Half Dozen" alongside of [[DOM]], [[2C-B]], [[2C-T-2]] & 7 and [[mescaline]]. | ||
= | == Usage == | ||
2C-E is mainly a recreational entheogen. It can be quite introspective in appropriate doses and settings. It doesn't lend itself well to intense party-like surroundings, much like LSD or similarly intense psychedelics. | 2C-E is mainly a recreational entheogen. It can be quite introspective in appropriate doses and settings. It doesn't lend itself well to intense party-like surroundings, much like LSD or similarly intense psychedelics. | ||
= Dosage = | == Dosage == | ||
{ | {{#tdose: 2ce }} | ||
== Duration == | |||
= Duration = | |||
Note: Duration can be significantly longer with higher doses. | Note: Duration can be significantly longer with higher doses. | ||
| Line 87: | Line 45: | ||
|} | |} | ||
= Effects = | == Effects == | ||
2C-E is a psychedelic phenethylamine and as such has psychedelic and stimulant effects. As with all psychedelics, different users are likely to experience different sets of effects, which usually include some however very rarely would include all of the following effects. | 2C-E is a psychedelic phenethylamine and as such has psychedelic and stimulant effects. As with all psychedelics, different users are likely to experience different sets of effects, which usually include some however very rarely would include all of the following effects. | ||
| Line 95: | Line 53: | ||
Note: The prevalence of negative effects increases with higher doses. | Note: The prevalence of negative effects increases with higher doses. | ||
== Positive == | === Positive === | ||
* Mood lift, euphoria, sense of well-being | * Mood lift, euphoria, sense of well-being | ||
| Line 111: | Line 69: | ||
* Increase in energy | * Increase in energy | ||
== Neutral == | === Neutral === | ||
* Time dilation | * Time dilation | ||
| Line 119: | Line 77: | ||
* Inability to focus or difficulty focusing | * Inability to focus or difficulty focusing | ||
== Negative == | === Negative === | ||
* Tension | * Tension | ||
| Line 135: | Line 93: | ||
* Racing thoughts | * Racing thoughts | ||
== Harm Reduction == | |||
= Harm Reduction = | |||
* As with all psychedelic drugs 2C-E carries with it the potential for a very powerful experience, and as such has the potential to create a very difficult experience ('bad' trip). Mindset and setting play important roles in governing the nature of a psychedelic experience, among other things. | * As with all psychedelic drugs 2C-E carries with it the potential for a very powerful experience, and as such has the potential to create a very difficult experience ('bad' trip). Mindset and setting play important roles in governing the nature of a psychedelic experience, among other things. | ||
| Line 142: | Line 99: | ||
See [[Psychedelics#Harm_Reduction|Psychedelic Harm Reduction]] for more information. | See [[Psychedelics#Harm_Reduction|Psychedelic Harm Reduction]] for more information. | ||
* As with all stimulants, care should be taken when dosing via different ROAs. The oral route has a much lower bioavailabity than those that bypass first pass metabolism i.e. | * As with all stimulants, care should be taken when dosing via different ROAs. The oral route has a much lower bioavailabity than those that bypass first pass metabolism i.e. Insufflated, rectal, intramuscular, intravenous and subcutaneous. | ||
See [[Stimulants#Harm Reduction|Stimulant Harm Reduction]] for more information. | See [[Stimulants#Harm Reduction|Stimulant Harm Reduction]] for more information. | ||
==Interactions== | === Interactions === | ||
See the [[Drug combinations]] chart for more information. | See the [[Drug combinations]] chart for more information. | ||
= Chemistry and Pharmacology = | == Chemistry and Pharmacology == | ||
==Chemistry== | === Chemistry === | ||
2,5-Dimethoxy-4-ethylphenethylamine is a colorless oil and analogue of mescaline. Similarly it is classified as a psychedelic phenethylamine. It shares the substituted amphetamine core found in the structure of many entactogens. Crystalline forms are obtained as the amine salt by reacting the free base with a mineral acid, typically HCl. It is soluble in both water and ethanol. Maximum concentration in H2O is reported at ~50mg/ml and it is said to be relatively stable in solution. A drop below normal ambient temperatures can cause particles to crystalize out. | 2,5-Dimethoxy-4-ethylphenethylamine is a colorless oil and analogue of mescaline. Similarly it is classified as a psychedelic phenethylamine. It shares the substituted amphetamine core found in the structure of many entactogens. Crystalline forms are obtained as the amine salt by reacting the free base with a mineral acid, typically HCl. It is soluble in both water and ethanol. Maximum concentration in H2O is reported at ~50mg/ml and it is said to be relatively stable in solution. A drop below normal ambient temperatures can cause particles to crystalize out. | ||
Shulgin does not report an exact boiling point for the free base, stating only that during one synthesis the fraction boiling between 90-100 °C at 0.25 mmHg pressure was collected and converted to the hydrochloride salt. Shulgin reports the melting point of the hydrochloride salt as 208.5-210.5 °C | Shulgin does not report an exact boiling point for the free base, stating only that during one synthesis the fraction boiling between 90-100 °C at 0.25 mmHg pressure was collected and converted to the hydrochloride salt. Shulgin reports the melting point of the hydrochloride salt as 208.5-210.5 °C. | ||
A full write up on Shulgin's synthesis for 2C-E can be found [https://www.erowid.org/library/books_online/pihkal/pihkal024.shtml here]. | A full write up on Shulgin's synthesis for 2C-E can be found [https://www.erowid.org/library/books_online/pihkal/pihkal024.shtml here]. | ||
==Pharmacology== | === Pharmacology === | ||
Like most psychedelic drugs, 2C-E is a 5-HT2a Agonist; from that, we can presume the concurrent or pre-administration of SSRIs may reduce the effects of 2C-E. 2C-E is one of the most potent of the 2C-X family, behind only 2C-P and 2C-T-4. The 2C-X family, specifically, 2C-E, 2C-I, and 2C-C all stimulated G protein binding, suggesting more of an activity similar to tryptamines such as 5-MeO-DMT and, interestingly, DPT. G Proteins are membrane proteins that effectively mediate interaction between hormone receptors and enzymes responsible for changes of metabolism as a result of hormonal changes. | Like most psychedelic drugs, 2C-E is a 5-HT2a Agonist; from that, we can presume the concurrent or pre-administration of SSRIs may reduce the effects of 2C-E. 2C-E is one of the most potent of the 2C-X family, behind only 2C-P and 2C-T-4. The 2C-X family, specifically, 2C-E, 2C-I, and 2C-C all stimulated G protein binding, suggesting more of an activity similar to tryptamines such as 5-MeO-DMT and, interestingly, DPT. G Proteins are membrane proteins that effectively mediate interaction between hormone receptors and enzymes responsible for changes of metabolism as a result of hormonal changes. | ||
| Line 166: | Line 123: | ||
In rats, Stage I metabolism involved deamination and O-Demthylation, which are related to the Monoamine oxidase (MAO) and cytochrome P450 (CYP) enzymes. For virtually all the 2C’s, (B,I,D,E,T-2, and T-7), MAO-A and MAO-B were reacted upon; interestingly, ½ of the molecules in Shulgin’s Magical Half Dozen (2C-E, 2C-T-2, 2C-T-7, with the addition of 2C-D) also act to a small extent on the CYP2D6 enzyme. Because of the commonality of these receptors, the 2C-X family is likely to be more reactive with other concurrently administered chemicals. | In rats, Stage I metabolism involved deamination and O-Demthylation, which are related to the Monoamine oxidase (MAO) and cytochrome P450 (CYP) enzymes. For virtually all the 2C’s, (B,I,D,E,T-2, and T-7), MAO-A and MAO-B were reacted upon; interestingly, ½ of the molecules in Shulgin’s Magical Half Dozen (2C-E, 2C-T-2, 2C-T-7, with the addition of 2C-D) also act to a small extent on the CYP2D6 enzyme. Because of the commonality of these receptors, the 2C-X family is likely to be more reactive with other concurrently administered chemicals. | ||
== LD50 == | === LD50 === | ||
The LD50 in humans is not currently known. Use caution when exploring high doses of this compound. | The LD50 in humans is not currently known. Use caution when exploring high doses of this compound. | ||
= Legal status = | == Legal status == | ||
* In Australia, 2C-E was added to the 'Dangerous Drugs' list of the 'Drugs Misuse Amendment Act 2008. | * In Australia, 2C-E was added to the 'Dangerous Drugs' list of the 'Drugs Misuse Amendment Act 2008. | ||
| Line 186: | Line 143: | ||
* In the USA, 2C-E is a Schedule I substance under the FDA Safety and Innovation act of 2012, and is illegal to possess, distribute or manufacture. | * In the USA, 2C-E is a Schedule I substance under the FDA Safety and Innovation act of 2012, and is illegal to possess, distribute or manufacture. | ||
= Links = | == Links == | ||
* [https://www.erowid.org/chemicals/2ce/ Erowid] | * [https://www.erowid.org/chemicals/2ce/ Erowid] | ||
| Line 195: | Line 152: | ||
[[Category:Stimulant]] | [[Category:Stimulant]] | ||
[[Category:Psychedelic]] | [[Category:Psychedelic]] | ||
[[Category:Drugs]] | [[Category:Drugs]] | ||
[[Category:Research Chemical]] | |||
Latest revision as of 16:09, 9 October 2018
2C-E is a chemical of the 2C-X series which is characterised by its particularly intense visuals and higher potency when compared with other members of the family.
History
2C-E, like many of its close analogues, was first synthesized by Alexander Shulgin and published in PiHKAL. He was quite fond of it, granting it a place in his "Magical Half Dozen" alongside of DOM, 2C-B, 2C-T-2 & 7 and mescaline.
Usage
2C-E is mainly a recreational entheogen. It can be quite introspective in appropriate doses and settings. It doesn't lend itself well to intense party-like surroundings, much like LSD or similarly intense psychedelics.
Dosage
{{#tdose: 2ce }}
Duration
Note: Duration can be significantly longer with higher doses.
Anecdotal evidence has shown the oral onset of 2C-E may vary wildly for some users, taking up to three hours before first effects in some cases.
| Onset | 60-90 minutes |
| Total | 9-14 hours |
| Onset | 20-40 minutes |
| Total | 6-9 hours |
Effects
2C-E is a psychedelic phenethylamine and as such has psychedelic and stimulant effects. As with all psychedelics, different users are likely to experience different sets of effects, which usually include some however very rarely would include all of the following effects.
Compared to other members of the 2C-X family, 2C-E is generally considered to have a heavier body load and to be more visual than its counterparts.
Note: The prevalence of negative effects increases with higher doses.
Positive
- Mood lift, euphoria, sense of well-being
- Enhanced sensory perception
- Increase in associative & creative thinking; introspection
- Life-changing 'spiritual' experiences
- Closed and Open eye visuals, patterning, tracers, color-enhancement, etc.
- Enhanced appreciation of music
- Increase in energy
Neutral
- Time dilation
- Slight increase in heart-rate and body temperature
- Inability to focus or difficulty focusing
Negative
- Tension
- Anxiety, restlessness, confusion
- Dizziness
- Nausea, gastrointestinal discomfort, possible vomiting
- Over-sensitivity to music or other sensory stimuli
- Unwanted 'spiritual' experiences
- Racing thoughts
Harm Reduction
- As with all psychedelic drugs 2C-E carries with it the potential for a very powerful experience, and as such has the potential to create a very difficult experience ('bad' trip). Mindset and setting play important roles in governing the nature of a psychedelic experience, among other things.
See Psychedelic Harm Reduction for more information.
- As with all stimulants, care should be taken when dosing via different ROAs. The oral route has a much lower bioavailabity than those that bypass first pass metabolism i.e. Insufflated, rectal, intramuscular, intravenous and subcutaneous.
See Stimulant Harm Reduction for more information.
Interactions
See the Drug combinations chart for more information.
Chemistry and Pharmacology
Chemistry
2,5-Dimethoxy-4-ethylphenethylamine is a colorless oil and analogue of mescaline. Similarly it is classified as a psychedelic phenethylamine. It shares the substituted amphetamine core found in the structure of many entactogens. Crystalline forms are obtained as the amine salt by reacting the free base with a mineral acid, typically HCl. It is soluble in both water and ethanol. Maximum concentration in H2O is reported at ~50mg/ml and it is said to be relatively stable in solution. A drop below normal ambient temperatures can cause particles to crystalize out.
Shulgin does not report an exact boiling point for the free base, stating only that during one synthesis the fraction boiling between 90-100 °C at 0.25 mmHg pressure was collected and converted to the hydrochloride salt. Shulgin reports the melting point of the hydrochloride salt as 208.5-210.5 °C.
A full write up on Shulgin's synthesis for 2C-E can be found here.
Pharmacology
Like most psychedelic drugs, 2C-E is a 5-HT2a Agonist; from that, we can presume the concurrent or pre-administration of SSRIs may reduce the effects of 2C-E. 2C-E is one of the most potent of the 2C-X family, behind only 2C-P and 2C-T-4. The 2C-X family, specifically, 2C-E, 2C-I, and 2C-C all stimulated G protein binding, suggesting more of an activity similar to tryptamines such as 5-MeO-DMT and, interestingly, DPT. G Proteins are membrane proteins that effectively mediate interaction between hormone receptors and enzymes responsible for changes of metabolism as a result of hormonal changes.
In rats, Stage I metabolism involved deamination and O-Demthylation, which are related to the Monoamine oxidase (MAO) and cytochrome P450 (CYP) enzymes. For virtually all the 2C’s, (B,I,D,E,T-2, and T-7), MAO-A and MAO-B were reacted upon; interestingly, ½ of the molecules in Shulgin’s Magical Half Dozen (2C-E, 2C-T-2, 2C-T-7, with the addition of 2C-D) also act to a small extent on the CYP2D6 enzyme. Because of the commonality of these receptors, the 2C-X family is likely to be more reactive with other concurrently administered chemicals.
LD50
The LD50 in humans is not currently known. Use caution when exploring high doses of this compound.
Legal status
- In Australia, 2C-E was added to the 'Dangerous Drugs' list of the 'Drugs Misuse Amendment Act 2008.
- In Denmark, 2C-E has been added to the list of Schedule B controlled substances.
- In New Zealand, 2C-E is illegal under the Analogues section of Schedule 3 / Class C, along with 2C-I, DOI, ephedrine and pseudoephedrine.
- In Sweden, 2C-E has been made illegal to sell or possess under their Act on the Prohibition of Certain Goods Dangerous to Health (lagen om förbud mot vissa hälsofarliga varor).
- In the UK, 2C-E is a Class A controlled Substance under the Misuse of Drugs Act's 2002 amendments and as such is illegal to possess to supply.
- In Germany, 2C-E is a Schedule I drug as of late 2014.
- In the USA, 2C-E is a Schedule I substance under the FDA Safety and Innovation act of 2012, and is illegal to possess, distribute or manufacture.